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challenging, as the virus is frequently detected in asymptomatic
patients, and coﬁndings with other respiratory viruses are
common. The clinical value of current diagnostic methods, such
as PCR, is therefore low, and alternative diagnostic strategies are
needed. We describe for the ﬁrst time the use of an antigen
detection assay for the rapid identiﬁcation of HBoV1 in a
paediatric patient with respiratory tract infection symptoms. We
estimate the duration of active HBoV1 infection to be 6 days.
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This is an oIntroductionHuman bocaviruses (HBoVs) are small single-stranded DNA
viruses which belong to the family Parvoviridae (subfamily Par-
vovirinae). Currently four HBoV species have been identiﬁed.
Human bocavirus 1 (HBoV1) was described for the ﬁrst time in
2005 in children with respiratory tract infection (RTI) [1].
Three other HBoVs, designated HBoV2, HBoV3 and HBoV4,
have mainly been detected in faeces, but a causal relation with
disease such as gastroenteritis is still unclear [2]. Prevalence
studies using nucleic acid ampliﬁcation methods show that
HBoV1 can be detected in 1.6 to 21.5% of children with
symptoms of RTI, particularly during winter and spring [3].
Seroepidemiology studies in the United States [4] and Italy [5]
indicated that over 90% of children had antibodies for HBoV
by 4 years of age.
PCR ampliﬁcation of viral nucleic acids is the most
commonly used technique for the detection of HBoV1 in res-
piratory samples. However, the true clinical impact of a positive
PCR result is often difﬁcult to assess as HBoV1 DNA may
persist for months in the respiratory tract. The DNA can be
encountered in both symptomatic patients and asymptomatic
individuals, as well as a coﬁnding in respiratory infections
caused by other pathogens [6].
Nevertheless, causative associations between HBoV1 infec-
tion and severe illness, including unexplained severe lower RTI
[7] and encephalitis [8], have been described. This emphasizes
the need for novel diagnostic methods for accurate and rapid
identiﬁcation of clinically relevant HBoV1 infections. Several
techniques for the diagnosis of HBoV1 infection have been
developed. These include serology [9], mRNA reverse tran-
scriptase (RT) PCR [10] and DNA PCR in serum and in nasal
samples [11]. However, these methods are cost and labour
intensive and are only available in highly specialized diagnostic
laboratories.
The mariPOC test system (ArcDia International Oy Ltd.,
Turku, Finland) provides a rapid alternative for HBoV1 detec-
tion. mariPOC is an automated and point-of-care compatible
test for rapid and simultaneous detection of antigens of eight
respiratory viruses (inﬂuenza A and B, respiratory syncytial
virus, adenovirus, human metapneumovirus and parainﬂuenza
type 1, 2 and 3 viruses) and Streptococcus pneumoniae from a
single nasopharyngeal sample. Detection of antigens is based on
separation-free two-photon excitation ﬂuorometry [12].
Recently a method to detect HBoV1 antigen was added to the
test panel. The new HBoV1 antigen test has an analytical
sensitivity of 3 ng/mL for recombinant HBoV-like particlesNew Microbe and New Infect 2016; 11: 17–19
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PCR designed to detect acute infection cases only (Toivola
et al., poster presented at 25th European Congress of Clinical
Microbiology and Infectious Diseases, 2015).
Here we describe the use of the HBoV1 antigen test for the
detection and monitoring of HBoV1 in nasopharyngeal samples.Case ReportFIG. 1. Detection of human bocavirus 1 (HBoV1) antigen by mariPOC
test (ArcDia International Oy Ltd., Turku, Finland) during course of
respiratory infection. Dashed line indicates cutoff for positive ﬁnding.
For each day of infection, nasopharyngeal sample was analysed by
HBoV1 antigen test.A previously healthy girl, 5 months of age, developed symptoms
of rhinorrhoea, cough and fever (temperature up to 39°C). The
consulting paediatrician diagnosed an upper RTI with no lower
respiratory tract involvement or signs of otitis. After written
parental consent was obtained, a nasopharyngeal swab was
taken on day 2 of illness and tested by the mariPOC for viro-
logic diagnosis. Within 20 minutes the sample tested positive
for HBoV1 antigen. Retrospective PCR testing conﬁrmed the
diagnosis: the nasopharyngeal sample tested positive for HBoV1
DNA by quantitative PCR [13] with a load of 7.7 × 107 copies/
mL and for HBoV1 mRNA by RT-PCR [10] with a Ct value of
26. To follow the course of infection, nasopharyngeal samples
were taken on days 3, 4 and 5 from the onset of symptoms.
While rhinorrhoea and mild cough continued, the fever
declined on day 3. An initial increase in mariPOC assay signal
was followed by a gradual decrease (Fig. 1). The viral antigen
concentrations were extrapolated from a dose–response curve
of a positive control dilution series. On day 6, the RTI symp-
toms were mild, which coincided with a decreasing HBoV1
antigen load.DiscussionWith the mariPOC rapid test system, we were able to in vitro
diagnose and monitor for the ﬁrst time the course of a pri-
mary HBoV1 RTI by directly targeting the virus proteins.
Compared to standard laboratory diagnostics, this rapid test is
easy to perform and may allow for a clinically accurate diag-
nosis of HBoV1 infection. The initial HBoV1 antigen detection
was conﬁrmed by both DNA and mRNA PCR. The costs of
the mariPOC multianalyte tests are comparable with other
antigen detection assays, such as direct ﬂuorescent antibody
testing. Compared to rapid and easy to perform nucleic acid
detection methods, e.g. PCR assays with integrated sample
preparation, mariPOC immunoassay is a less expensive
alternative.
mariPOC test results are typically reported as qualitative. In
this study we followed the course of the HBoV1 infection by
using the quantitative property of the underlying two-photonNew Microbes and New Infections © 2016 The Authors. Published by Elsevier Ltd on behalf of
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limits the quantitativeness of the data to semiquantitative. We
showed the duration of this HBoV1 active infection to be
approximately 1 week. The patient was HBoV1 antigen posi-
tive the morning after onset of symptoms, and HBoV1 antigen
positivity lasted until day 5, when the signal barely exceeded
the diagnostic threshold. No sample was available beyond day
5, while the decline in antigen since day 3 and the near-cutoff
result on day 5 strongly suggest that the patient would have
been negative on day 6. These results are in line with the time
span of other respiratory viruses [14] and demonstrate once
more that rapid testing should be done as soon as possible
after the onset of symptoms and at the latest within 5 to 6
days.
While most HBoV1 infections are self-limited, they some-
times lead to life-threatening conditions. The availability of a
rapid and accurate test for HBoV1 is likely to be useful in dif-
ferential diagnoses and development of therapy, and will in-
crease our understanding of the epidemiology and clinical
impact of HBoV1 infections.AcknowledgementsSupported in part by the Seventh Framework Programme of
the European Union Marie Curie IAPP under contract PIAPP-
GA-2013-612308 and partly supported by TEKES, the Finnish
Funding Agency for Innovation, under the project name ‘Get it
done!,’ funding decision 534/14. We thank both the patient and
her parents for participating in this study and enabling the re-
searchers to precisely follow the course of the infection by
testing multiple consecutive samples.European Society of Clinical Microbiology and Infectious Diseases, NMNI, 11, 17–19
.0/)
NMNI Bruning et al. Human bocavirus 1 infection 19Conﬂict of InterestHT, HA and JOK are R&D employees at ArcDia International
Oy Ltd. The other authors declare no conﬂict of interest.References[1] Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A,
Andersson B. Cloning of a human parvovirus by molecular screening of
respiratory tract samples. Proc Natl Acad Sci U S A 2005;102:12891–6.
[2] Paloniemi M, Lappalainen S, Salminen M, Katka M, Kantola K,
Hedman L, et al. Human bocaviruses are commonly found in stools of
hospitalized children without causal association to acute gastroenter-
itis. Eur J Pediatr 2014;173:1051–7.
[3] Dunn JJ, Miller MB. Emerging respiratory viruses other than inﬂuenza.
Clin Lab Med 2014;34:409–30.
[4] Kahn JS, Kesebir D, Cotmore SF, D’Abramo Jr A, Cosby C, Weibel C,
et al. Seroepidemiology of human bocavirus deﬁned using recombinant
virus-like particles. J Infect Dis 2008;198:41–50.
[5] Guido M, Zizza A, Bredl S, Lindner J, De Donno A, Quattrocchi M,
et al. Seroepidemiology of human bocavirus in Apulia, Italy. Clin
Microbiol Infect 2012;18:E74–6.
[6] Martin ET, Kuypers J, McRoberts JP, Englund JA, Zerr DM. Human
bocavirus 1 primary infection and shedding in infants. J Infect Dis.
2015;212:516–24.New Microbes and New Infections © 2016 The Authors. Published by Elsevier Ltd on behal
This is an o[7] Moesker FM, van Kampen JJ, van der Eijk AA, van Rossum AM, de
Hoog M, Schutten M, et al. Human bocavirus infection as a cause of
severe acute respiratory tract infection in children. Clin Microbiol
Infect 2015;21:964.e1–8.
[8] Mitui MT, Tabib SM, Matsumoto T, Khanam W, Ahmed S, Mori D,
et al. Detection of human bocavirus in the cerebrospinal ﬂuid of
children with encephalitis. Clin Infect Dis 2012;54:964–7.
[9] Kantola K, Hedman L, Allander T, Jartti T, Lehtinen P, Ruuskanen O,
et al. Serodiagnosis of human bocavirus infection. Clin Infect Dis
2008;46:540–6.
[10] Christensen A, Dollner H, Skanke LH, Krokstad S, Moe N,
Nordbo SA. Detection of spliced mRNA from human bocavirus 1 in
clinical samples from children with respiratory tract infections. Emerg
Infect Dis 2013;19:574–80.
[11] Allander T, Jartti T, Gupta S, Niesters HG, Lehtinen P, Osterback R,
et al. Human bocavirus and acute wheezing in children. Clin Infect Dis
2007;44:904–10.
[12] Koskinen JO, Vainionpaa R, Meltola NJ, Soukka J, Hanninen PE,
Soini AE. Rapid method for detection of inﬂuenza A and B virus an-
tigens by use of a two-photon excitation assay technique and dry-
chemistry reagents. J Clin Microbiol 2007;45:3581–8.
[13] Kantola K, Sadeghi M, Antikainen J, Kirveskari J, Delwart E, Hedman K,
et al. Real-time quantitative PCR detection of four human bocaviruses.
J Clin Microbiol 2010;48:4044–50.
[14] Suryaprasad A, Morgan OW, Peebles P, Warner A, Kerin TK,
Esona MD, et al. Virus detection and duration of illness among patients
with 2009 pandemic inﬂuenza A (H1N1) virus infection in Texas. Clin
Infect Dis 2011;52(Suppl. 1):S109–15.f of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 11, 17–19
pen access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
